Most Read Articles
14 Feb 2020
Chronic pancreatitis patients taking antioxidants (AO) supplementation show a sustained increase in blood levels of AO, but no additional benefit is seen on endocrine and exocrine functions, markers of fibrosis, oxidative stress (OS) and inflammation, nutritional status, pain, and quality of life (QOL) when compared with those on placebo, according to a study.
Roshini Claire Anthony, 12 Feb 2020

Children with inflammatory bowel disease (IBD) do not appear to have an elevated risk of lymphoma following treatment with anti-tumour necrosis factor (TNF) agents, according to a study presented at the recent Crohn’s and Colitis Congress 2020.

Jairia Dela Cruz, 3 days ago
A diet low in fat and high in fibre seems well tolerated in patients with ulcerative colitis, not contributing to increased inflammation while significantly increasing populations of Faecalibacterium prausnitzii, according to a study presented at the 2020 Crohn's & Colitis Congress.
Pearl Toh, 14 Feb 2020
Donor selection for faecal microbiota transplant (FMT) can make a difference to maintenance of long-term remission in patients with ulcerative colitis (UC), reveals a study presented at the 2020 Crohn's & Colitis Congress (CCC).

Peppermint oil mostly ineffective for IBS

26 Jan 2020

Peppermint oil, regardless of whether it is released in the small intestine or in the ileocolon, is ineffective for overall symptom relief in irritable bowel syndrome (IBS), a new study has found. In contrast, it shows significant efficacy for abdominal pain, discomfort and disease severity.

Researchers randomly assigned 189 IBS patients to receive either 182-mg small-intestinal release (n=62; mean age, 32.0±11.0 years; 82.3 percent female) or 182-mg ileocolonic release (n=63; mean age, 34.4±13.1 years; 74.6 percent female) peppermint oil, or placebo (n=64; mean age, 35.5±15.2 years; 76.6 percent female).

The primary study outcome was abdominal pain response, which was defined as a drop in the weekly average of worst daily pain of at least 30 percent relative to baseline. This metric did not significantly differ in either the small-intestinal release (p=0.170) or ileocolonic release (p=0.385) peppermint oil group relative to placebo.

Similarly, global relief response was not significantly greater in either peppermint oil group relative to placebo (p=0.317 and p=0.351, respectively).

Exploratory secondary outcome analyses, however, found that small-intestinal release peppermint oil led to greater drops in 8-week daily worst abdominal pain vs placebo (p=0.016). This was also true for abdominal discomfort at weeks 6 (p=0.020), 7 (p=0.009) and 8 (p=0.025). There was also a significant positive effect on IBS symptom severity at week 8 (p=0.02).

Moreover, both peppermint groups reported significantly rarer use of rescue medication for pain. Ileocolonic release of peppermint oil had no significant effect on relief, reduction of abdominal discomfort, abdominal pain or IBS symptom severity.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
14 Feb 2020
Chronic pancreatitis patients taking antioxidants (AO) supplementation show a sustained increase in blood levels of AO, but no additional benefit is seen on endocrine and exocrine functions, markers of fibrosis, oxidative stress (OS) and inflammation, nutritional status, pain, and quality of life (QOL) when compared with those on placebo, according to a study.
Roshini Claire Anthony, 12 Feb 2020

Children with inflammatory bowel disease (IBD) do not appear to have an elevated risk of lymphoma following treatment with anti-tumour necrosis factor (TNF) agents, according to a study presented at the recent Crohn’s and Colitis Congress 2020.

Jairia Dela Cruz, 3 days ago
A diet low in fat and high in fibre seems well tolerated in patients with ulcerative colitis, not contributing to increased inflammation while significantly increasing populations of Faecalibacterium prausnitzii, according to a study presented at the 2020 Crohn's & Colitis Congress.
Pearl Toh, 14 Feb 2020
Donor selection for faecal microbiota transplant (FMT) can make a difference to maintenance of long-term remission in patients with ulcerative colitis (UC), reveals a study presented at the 2020 Crohn's & Colitis Congress (CCC).